Penumbra (PEN) Stock Forecast & Price Target

Compare

450 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

PEN Analyst Ratings

Moderate Buy

13 Buy

5 Hold

0 Sell

Based on 18 analysts giving stock ratings to

Penumbra

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

PEN Stock 12 Month Forecast

Average Price Target

$305.87

▲(21.68% Upside)

Based on 18 Wall Street analysts offering 12 month price targets for Penumbra in the last 3 months. The average price target is $305.87 with a high forecast of $350.00 and a low forecast of $265.00. The average price target represents a 21.68% change from the last price of $251.37.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"170":"$170","351":"$351","215.25":"$215.3","260.5":"$260.5","305.75":"$305.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":350,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$350.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":305.87,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$305.87</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":265,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$265.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[170,215.25,260.5,305.75,351],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,243.01,251.23999999999998,259.46999999999997,267.7,275.93,284.15999999999997,292.39,300.62,308.85,317.08,325.31,333.53999999999996,341.77,{"y":350,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,243.01,247.8453846153846,252.68076923076922,257.5161538461538,262.35153846153844,267.18692307692305,272.02230769230766,276.85769230769233,281.69307692307694,286.52846153846156,291.36384615384617,296.1992307692308,301.0346153846154,{"y":305.87,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,243.01,244.70153846153846,246.3930769230769,248.08461538461538,249.77615384615385,251.4676923076923,253.15923076923076,254.85076923076923,256.5423076923077,258.2338461538462,259.9253846153846,261.61692307692306,263.30846153846153,{"y":265,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":171.25,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":202.32,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":191.56,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":233.3,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":244.84,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":237.48,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":266.97,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":285.44,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":271.13,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":291.82,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":256.16,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":250.68,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":243.01,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$350.00

Average Price Target$305.87

Lowest Price Target$265.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Lila Implantra

TR | OpenAI - 4o

$268→$280

Buy

11.39%

Upside

Reiterated

08/13/25

AI Generated ArticleAI Generated Article

William Plovanic

Canaccord Genuity

$350

Buy

39.24%

Upside

Reiterated

08/12/25

Penumbra's Strategic Growth Initiatives and Market Expansion Drive Buy Rating

Shagun Singh Chadha

RBC Capital

$325

Buy

29.29%

Upside

Reiterated

08/11/25

RBC Capital Sticks to Its Buy Rating for Penumbra (PEN)

Patrick Wood

Morgan Stanley

$260→$266

Hold

5.82%

Upside

Reiterated

07/31/25

Morgan Stanley Remains a Hold on Penumbra (PEN)

Priya Sachdeva

UBS

$330→$335

Buy

33.27%

Upside

Reiterated

07/31/25

Penumbra price target raised to $335 from $330 at UBSPenumbra price target raised to $335 from $330 at UBS

Richard Newitter

Truist Financial

$300→$310

Buy

23.32%

Upside

Reiterated

07/30/25

Truist Financial Reaffirms Their Buy Rating on Penumbra (PEN)

Larry Biegelsen

Wells Fargo

$315→$290

Buy

15.37%

Upside

Reiterated

07/30/25

Analysts Conflicted on These Healthcare Names: Merck & Company (NYSE: MRK), Incyte (NASDAQ: INCY) and Penumbra (NYSE: PEN)

Robbie Marcus

J.P. Morgan

$285→$265

Hold

5.42%

Upside

Reiterated

07/30/25

Penumbra (PEN) Gets a Hold from J.P. Morgan

Christopher Pasquale

Nephron

$305

Buy

21.34%

Upside

Upgraded

07/30/25

Positive Report for Penumbra (PEN) from Nephron

David Rescott

Robert W. Baird

$283→$285

Buy

13.38%

Upside

Reiterated

07/30/25

Penumbra price target raised to $285 from $283 at BairdPenumbra price target raised to $285 from $283 at Baird

Mike Kratky

Leerink Partners

$327

Buy

30.09%

Upside

Reiterated

07/30/25

Penumbra's Strong Growth Potential and Strategic Developments Reinforce Buy RatingWe are reiterating our Outperform rating on PEN and maintaining our $327 PT following the company's 2Q results. PEN reported WW sales +4% vs. consensus, with WW Thrombectomy +1% vs. consensus and WW E&A sales +11% vs. consensus. We were particularly encouraged by another consecutive quarter of strong growth in VTE, with PEN's US VTE business growing +42% y/y. MSD growth of PEN's US Stroke business came in a bit soft, with the company citing flat market growth, though our sense is that expectations were low coming into the print. Notably, PEN announced an expansion of its sales force, including the addition of new E&A reps while existing reps focus more exclusively on PEN's thrombectomy business.

Brandon Vazquez

William Blair

―

Buy

―

Reiterated

07/30/25

Penumbra's Promising Outlook: Buy Rating Amid Strong Performance and Strategic Growth OpportunitiesWednesday, July 30, 2025 12:59 AM William Blair Equity Research | Healthcare Penumbra, Inc.

Ryan Zimmerman

BTIG

$320

Buy

27.30%

Upside

Reiterated

07/30/25

BTIG Remains a Buy on Penumbra (PEN)

Michael Matson

Needham

―

Hold

―

Reiterated

07/30/25

Needham Sticks to Their Hold Rating for Penumbra (PEN)

Michael Sarcone

Jefferies

$325

Buy

29.29%

Upside

Reiterated

07/23/25

Jefferies Reaffirms Their Buy Rating on Penumbra (PEN)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Lila Implantra

TR | OpenAI - 4o

$268→$280

Buy

11.39%

Upside

Reiterated

08/13/25

AI Generated ArticleAI Generated Article

William Plovanic

Canaccord Genuity

$350

Buy

39.24%

Upside

Reiterated

08/12/25

Penumbra's Strategic Growth Initiatives and Market Expansion Drive Buy Rating

Shagun Singh Chadha

RBC Capital

$325

Buy

29.29%

Upside

Reiterated

08/11/25

RBC Capital Sticks to Its Buy Rating for Penumbra (PEN)

Patrick Wood

Morgan Stanley

$260→$266

Hold

5.82%

Upside

Reiterated

07/31/25

Morgan Stanley Remains a Hold on Penumbra (PEN)

Priya Sachdeva

UBS

$330→$335

Buy

33.27%

Upside

Reiterated

07/31/25

Penumbra price target raised to $335 from $330 at UBSPenumbra price target raised to $335 from $330 at UBS

Richard Newitter

Truist Financial

$300→$310

Buy

23.32%

Upside

Reiterated

07/30/25

Truist Financial Reaffirms Their Buy Rating on Penumbra (PEN)

Larry Biegelsen

Wells Fargo

$315→$290

Buy

15.37%

Upside

Reiterated

07/30/25

Analysts Conflicted on These Healthcare Names: Merck & Company (NYSE: MRK), Incyte (NASDAQ: INCY) and Penumbra (NYSE: PEN)

Robbie Marcus

J.P. Morgan

$285→$265

Hold

5.42%

Upside

Reiterated

07/30/25

Penumbra (PEN) Gets a Hold from J.P. Morgan

Christopher Pasquale

Nephron

$305

Buy

21.34%

Upside

Upgraded

07/30/25

Positive Report for Penumbra (PEN) from Nephron

David Rescott

Robert W. Baird

$283→$285

Buy

13.38%

Upside

Reiterated

07/30/25

Penumbra price target raised to $285 from $283 at BairdPenumbra price target raised to $285 from $283 at Baird

Mike Kratky

Leerink Partners

$327

Buy

30.09%

Upside

Reiterated

07/30/25

Brandon Vazquez

William Blair

―

Buy

―

Reiterated

07/30/25

Penumbra's Promising Outlook: Buy Rating Amid Strong Performance and Strategic Growth OpportunitiesWednesday, July 30, 2025 12:59 AM William Blair Equity Research | Healthcare Penumbra, Inc.

Ryan Zimmerman

BTIG

$320

Buy

27.30%

Upside

Reiterated

07/30/25

BTIG Remains a Buy on Penumbra (PEN)

Michael Matson

Needham

―

Hold

―

Reiterated

07/30/25

Needham Sticks to Their Hold Rating for Penumbra (PEN)

Michael Sarcone

Jefferies

$325

Buy

29.29%

Upside

Reiterated

07/23/25

Jefferies Reaffirms Their Buy Rating on Penumbra (PEN)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Penumbra

1 Month

xxx

Success Rate

16/22 ratings generated profit

Average Return

+6.65%

reiterated a xxx

rating 13 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 72.73% of your transactions generating a profit, with an average return of +6.65% per trade.

3 Months

xxx

Success Rate

11/18 ratings generated profit

Average Return

+6.46%

reiterated a xxx

rating 25 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 61.11% of your transactions generating a profit, with an average return of +6.46% per trade.

1 Year

Richard NewitterTruist Financial

Success Rate

11/16 ratings generated profit

Average Return

+0.96%

reiterated a buy rating 25 days ago

Copying Richard Newitter's trades and holding each position for 1 Year would result in 68.75% of your transactions generating a profit, with an average return of +0.96% per trade.

2 Years

xxx

Success Rate

17/24 ratings generated profit

Average Return

+10.09%

reiterated a xxx

rating 12 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 70.83% of your transactions generating a profit, with an average return of +10.09% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PEN Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, PEN has received 23 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. PEN average Analyst price target in the past 3 months is 305.87.

Each month's total comprises the sum of three months' worth of ratings.

PEN Financial Forecast

PEN Earnings Forecast

Next quarter’s earnings estimate for PEN is $0.92 with a range of $0.85 to $1.03. The previous quarter’s EPS was $0.86. PEN beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 50.00% of the time in the same period. In the last calendar year PEN has Outperformed its overall industry.

PEN Sales Forecast

Next quarter’s sales forecast for PEN is $340.72M with a range of $336.19M to $344.00M. The previous quarter’s sales results were $339.45M. PEN beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 55.07% of the time in the same period. In the last calendar year PEN has Outperformed its overall industry.

PEN Stock Forecast FAQ

What is PEN’s average 12-month price target, according to analysts?

Based on analyst ratings, Penumbra’s 12-month average price target is 305.87.

What is PEN’s upside potential, based on the analysts’ average price target?

Penumbra has 21.68% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is PEN a Buy, Sell or Hold?

Penumbra has a consensus rating of Moderate Buy which is based on 13 buy ratings, 5 hold ratings and 0 sell ratings.

What is Penumbra’s price target?

The average price target for Penumbra is 305.87. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $350.00 ,the lowest forecast is $265.00. The average price target represents 21.68% Increase from the current price of $251.37.

What do analysts say about Penumbra?

Penumbra’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 18 Wall Streets Analysts.

How can I buy shares of PEN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Penumbra (PEN) Stock Forecast & Price Target

PEN Analyst Ratings

PEN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Penumbra

PEN Analyst Recommendation Trends

PEN Financial Forecast

PEN Earnings Forecast

PEN Sales Forecast

PEN Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts